Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Process for making hepatitis b core protein modulators

A technology of acylating agent and compound, which is applied in the field of preparing hepatitis B core protein regulator, and can solve the problems such as poor tolerance of side effects of interferon alpha

Pending Publication Date: 2019-12-24
ASSEMBLY BIOSCI
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Interferon alfa has severe side effects and is poorly tolerated in patients and is only successful in a small percentage of patients due to limited treatment strategies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for making hepatitis b core protein modulators
  • Process for making hepatitis b core protein modulators
  • Process for making hepatitis b core protein modulators

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] Example 1: Synthesis of (2-(trifluoromethyl)thiazol-5-yl)methanamine

[0122]

[0123] Step 1: Preparation of 1,3-bis(trifluoroacetylamino)-2-propanol (1-2):

[0124] The title compound was prepared as follows according to the method described in the Supporting Information section of Org. Lett. 2008, 10, 2935-2938. At 0°C, a solution of trifluoroacetic anhydride (7kg, 4.66mol) in 15L of anhydrous acetonitrile was added dropwise to 1,3-diaminopropan-2-ol (1kg, 1.11mol) and triethylamine (3.38 kg; 3.33 mol) in a solution in anhydrous acetonitrile (13.3 L). After 2 hours, the reaction mixture was warmed to room temperature and stirred for 14 hours. The volatiles were removed and the residue was dissolved in ethyl acetate (20 L) and washed sequentially with saturated aqueous sodium bicarbonate, saturated ammonium chloride and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give a solid. The solid was suspended in petrole...

Embodiment 2

[0131] Example 2: Synthesis of (2-ethylthiazol-5-yl)methanamine hydrochloride (2-7) via an alternative route:

[0132]

[0133] Step 1: Synthesis of ethyl 2-chloro-3-oxopropionate (2-2):

[0134] 2-Chloroacetate ethyl 2-1 (5 g, 40.98 mmol) and ethyl formate (3.03 g, 40.98 mmol) in diisopropyl To a solution in ether (100 mL) was added potassium tert-butoxide (5.49 g, 45.08 mmol) in portions; warmed to room temperature and stirred for 24 hours. The reaction was monitored by TLC; upon completion of the reaction, the pH of the reaction mixture was adjusted to about 6 using 5N HCl. The obtained solid was filtered, washed with diethyl ether (200 mL), and dried in vacuo to give compound 2-2 (6 g) as a light brown syrup. TLC: 30% EtOAc / hexane (R f : 0.2); LC-MS: 21.49%+75.58%; 149.0 (M + -1); (column; X-Select C-18, (50×3.0mm, 3.5μm); RT 0.56min, 0.77min.5Mm NH 4 OAc in water: ACN 0.8 mL / min).

[0135] Step 2: Synthesis of ethyl 2-ethylthiazole-5-carboxylate (2-3):

[0136] ...

Embodiment 3

[0145] Example 3: 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine -Synthesis of 8-formic acid 5,5-dioxide (3-7):

[0146]

[0147] Step 1: Preparation of methyl 4-((2-(methoxycarbonyl)phenyl)thio)-3-nitrobenzoate (3-3):

[0148] Add methyl 4-fluoro-3-nitrobenzoate (300 g, 1.0 equiv) and methyl thiosalicylate (278.7 g, 1.1 equiv) in DMF (1.8 L) under stirring at 0 to 5° C. Cs was added batchwise to the solution in 2 CO 3 (589 g, 1.2 equiv). The reaction mixture was stirred at 0 to 5°C for 30 minutes, warmed to room temperature over 2 hours and stirred at room temperature for 2 hours. The reaction mixture was cooled to 10-15°C, diluted with water (26V) and stirred for 30 minutes. The solid was collected by filtration, washed with water (20V) and n-heptane (10V), and dried under reduced pressure at a temperature below 50°C. The dried solid was suspended in n-heptane (10V) at 90-95°C to form a slurry and cooled to 35-40°C. The solid was collected by filtration, washed w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.

Description

[0001] related application [0002] This application claims priority to and benefit of U.S. Provisional Application No. 62 / 470,560, filed March 13, 2017, which is hereby incorporated by reference in its entirety. Background technique [0003] Hepatitis B (HBV) causes viral hepatitis, which can further lead to chronic liver disease and increase the risk of cirrhosis and liver cancer (hepatocellular carcinoma). Worldwide, about 2 billion people have been infected with HBV, about 360 million people are chronically infected, and HBV infection causes more than 500,000 deaths every year. HBV can be transmitted through bodily fluids: from mother to child, sexually and through blood products. Children born to HBV-positive mothers can also become infected unless vaccinated at birth. [0004] The hepatitis virus particle consists of a lipid envelope covered with surface proteins (HBsAg) surrounding the viral core. The core consists of a protein shell or capsid composed of 120 core pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D417/12
CPCC07D417/12A61P31/20A61K31/554C07C231/10C07C231/12C07C315/02C07C315/04C07C319/14C07C319/20
Inventor L.李L.D.阿诺德S.雷迪
Owner ASSEMBLY BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com